Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best biotech stocks with high potential. In a report released on October 3, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $145.00.

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported in its fiscal Q2 2025 results that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. The company had $293.8 million of cash, cash equivalents, and marketable securities at quarter end

In addition, cash at the end of fiscal Q2 2025 excluded $230 million of gross proceeds that Soleno Therapeutics, Inc. (NASDAQ:SLNO) raised in July through an underwritten offering of common stock.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) also reported that product revenue, net, for the quarter reached $32.7 million.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics to treat rare diseases.

The company focuses on the treatment of neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).

While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.